Complete Guide to “Non-Traditional” Intestinal Markers: Tumor M2-PK, Fecal Calprotectin, Cologuard Test, and FOBT — How Do They Help You Screen and Monitor? – OncoExpertAi

Have you recently received a lab result with the term “elevated fecal calprotectin” or have you heard of the Cologuard test and don’t know what it means? Or has your doctor recommended a marker called Tumor M2-PK and you can’t find clear information online? You’ve come to the right place. This guide explains in a simple way what these lesser-known intestinal markers are, how to interpret their values, and — most importantly — what medical decisions they can influence.

Why do we need intestinal markers “other than colonoscopy”?

Colorectal cancer (cancer of the colon and rectum) is one of the most common forms of cancer worldwide. Romania is, unfortunately, among the European countries with the highest mortality from this disease — partly due to late diagnosis. Colonoscopy remains the “gold standard” for screening and diagnosis, but it is an invasive procedure, requires special training and is not accessible to everyone in a timely manner.

Intestinal markers in blood or feces come as complementary tools. They do not replace colonoscopy, but they can signal when it is truly necessary , monitor the effectiveness of ongoing treatment, or differentiate serious intestinal inflammation from benign one.

1. FOBT and FIT — the “classics” of detecting blood in the stool

What are they?

FOBT (Fecal Occult Blood Test) and FIT (Fecal Immunochemical Test) detect microscopic traces of blood in the stool — blood that is not visible to the naked eye, but may come from a polyp or colorectal cancer.

FIT is the modern and more specific variant: it recognizes exclusively human hemoglobin and is not influenced by diet (there is no need to avoid red meat or vitamin C before the test).
FOBT (older version) can give false positive results if you have consumed certain foods or medications.

Reference values and interpretation

Negative : normal; no signs of detectable active bleeding
Positive : requires mandatory colonoscopy to rule out cancer

FIT is recommended annually in standard-risk adults starting at age 45 (according to the 2021 updated ACS guidelines). Its sensitivity for colorectal cancer is approximately 79%, making it a simple, inexpensive, and doable at-home screening.

⚠️ Important: A positive FIT does not automatically mean cancer. Benign polyps, hemorrhoids, or anal fissures can also produce a positive result. Confirmatory colonoscopy is essential.

2. Fecal calprotectin — the thermometer of intestinal inflammation

What is it and why is it important?

Calprotectin is a protein released by inflammatory cells (neutrophils) when there is active inflammation in the intestine. It is measured from a small stool sample and is a reliable indicator of the intensity of intestinal inflammation.

Reference values

< 50 µg/g feces : Normal
50–200 µg/g : Mild inflammation or borderline result; requires repeat or clinical evaluation
> 200 µg/g : Moderate-severe inflammation; increased risk of active inflammatory bowel disease

The most important application: IBD versus irritable bowel syndrome

Fecal calprotectin is extremely useful in differentiating Crohn’s disease or ulcerative colitis (inflammatory bowel disease — IBD) from irritable bowel syndrome (IBS) :

In irritable bowel syndrome (IBS) : calprotectin is usually normal (<50 µg/g)
In active IBD (Crohn’s, ulcerative colitis): calprotectin is usually elevated (>200 µg/g)

Role in monitoring biological treatment

Fecal calprotectin is a valuable tool for patients with IBD undergoing treatment. A decreasing value after initiation of biological therapy (infliximab, adalimumab, vedolizumab, etc.) signals a favorable therapeutic response — often months before endoscopy visually confirms mucosal remission. The European ECCO guidelines recommend its monitoring 8–12 weeks after a change in biological therapy.

3. Fecal lactoferrin — calprotectin’s ally

Lactoferrin is another protein released from inflammatory cells during active intestinal inflammation.

Normal values : < 7 µg/mL
Elevated values : Moderate–high intensity intestinal inflammation

It has similar indications to calprotectin and may be useful when calprotectin gives a borderline result and the doctor wants further confirmation of active inflammation.

4. Tumor M2-PK — the metabolic marker of tumor cells

A completely different approach: what does the cancer cell do with glucose?

Tumor M2-PK is one of the most innovative intestinal markers available. Unlike classic markers that detect blood or inflammation, Tumor M2-PK measures the metabolic activity of tumor cells — that is, “how the cancer uses energy.”

Cancer cells “consume” glucose differently than healthy cells. They preferentially use an inactive (dimeric) form of the enzyme pyruvate kinase M2 — a metabolic adaptation that allows them to rapidly produce the materials needed for uncontrolled multiplication. This dimeric form is released into both the blood and feces and can be detected by specific tests.

Reference values

Sample type	Normal value
Plasma (EDTA blood)	< 15 U/mL
Feces	< 4 U/mL

What can Tumor M2-PK detect?

Tumor M2-PK is not specific to a single organ — it reflects the overall metabolic aggressiveness of tumor cells. At a threshold of 15 U/mL in plasma, the diagnostic performance is:

Tumor type	Sensitivity	Specificity
Colorectal cancer	57%	89%
Gastric/esophageal cancer	62%	89%
Pancreatic cancer	72%	89%

How is it used in practice?

Tumor M2-PK is not used alone for diagnosis — it is effective in combination with classical markers :

CEA — for colorectal cancer
CA 72-4 — for gastric cancer
CA 19-9 — for pancreatic cancer

Combining Tumor M2-PK with these markers significantly increases detection sensitivity over using either marker alone.

Tumor M2-PK in post-treatment monitoring

One of the most valuable roles of this marker is monitoring after surgical treatment :

Levels return to normal within 6–11 weeks after successful tumor excision
Persistence or return of elevated values signals recurrence or metastasis

This makes it a practical tool for post-operative oncological surveillance, adding valuable clinical information beyond imaging.

5. Cologuard test — stool DNA test for colorectal cancer

How does it work?

three types of molecular signs of colorectal cancer in feces :

Genetic mutations in the KRAS gene — frequently present in colorectal cancer
Aberrant methylation of the NDRG4 and BMP3 genes — DNA changes characteristic of cancer cells
Fecal hemoglobin — detected by immunochemical method, similar to FIT

What performance does it have?

Cologuard Plus (second generation, launched in 2024) has demonstrated:

94% sensitivity for confirmed colorectal cancer
Sensitivity 43% for advanced adenomas (high-risk polyps)

Who should get Cologuard?

Standard -risk adults (no personal or family history of colorectal cancer), aged ≥ 45 years
Recommended interval: every 1–3 years (compared to FIT, which is recommended annually)

⚠️ A positive Cologuard result requires a confirmatory colonoscopy. The test identifies molecular markers of risk — it does not definitively diagnose cancer.

Therapeutic implications: how do these markers influence treatment decisions?

Marker	Therapeutic implication
Elevated fecal calprotectin under biological therapy	Signals lack of response → justifies dose adjustment or change of biological
Persistently increased M2-PK tumor post-surgery	Suggests residual disease or relapse → requires follow-up imaging and oncological evaluation
Tumor M2-PK decreasing under chemotherapy	Sign of favorable therapeutic response → supports continuation of current regimen
FIT/Cologuard positive	Requires colonoscopy → if cancer is identified at an early stage, 5-year survival exceeds 90%

Colorectal cancer detected at stage I has a 5-year survival rate of over 90% , compared to less than 15% at stage IV—this is the strength of active screening.

Quick summary: intestinal markers table

Marker	Sample type	Normal value	Main use
FIT/FOBT	Feces	Negative	Colorectal cancer screening (annual)
Fecal calprotectin	Feces	< 50 µg/g	Diagnosing IBD vs. IBS; monitoring treatment
Fecal lactoferrin	Feces	< 7 µg/mL	Confirmation of intestinal inflammation
Tumor M2-PK (plasma)	Blood (EDTA)	< 15 U/mL	Screening + monitoring of digestive tumors
M2-PK tumor (feces)	Feces	< 4 U/mL	Colorectal cancer screening
Cologuard	Feces	Negative	Colorectal cancer screening by DNA (at 1–3 years)

How can Oncoexpertai help you interpret these analyses?

If you have received positive or borderline results for any of these markers and are unsure of the next step, the Oncoexpertai.com platform can provide you with a structured starting point. Our advanced Artificial Intelligence algorithms correlate your marker values with current international guidelines (NCCN, ESMO, ECCO) and generate a preliminary analysis that you can use as a basis for discussion with your oncologist or gastroenterologist.

Technology does not replace the doctor — it gives you the certainty that you arrive at the consultation with a complete file and the right questions .

Disclaimer: The information in this article is for informational and educational purposes only. It does not constitute a medical diagnosis, does not replace the consultation of a specialist doctor, and does not represent a personalized therapeutic recommendation. Any medical decision should be made exclusively after consultation with a qualified doctor, based on a complete assessment of your health condition. Reference values may vary slightly depending on the laboratory and method used — always refer to the ranges indicated on the analysis report.

Bibliography

US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. doi:10.3322/caac.21457.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297. doi:10.1056/NEJMoa1311194.
Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):984-993. doi:10.1056/NEJMoa2310336.
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113.
Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802-819. doi:10.1038/ajg.2015.120.
Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012;18(30):4004-4011. doi:10.3748/wjg.v18.i30.4004.

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI

Onisim Florin

Login